{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T06:17:24Z","timestamp":1781849844832,"version":"3.54.5"},"reference-count":90,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009367","name":"Mansoura University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009367","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.bioorg.2025.109366","type":"journal-article","created":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T16:04:57Z","timestamp":1765641897000},"page":"109366","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Dual topoisomerase II\u03b1\/EGFR-TK inhibitors: Synthesis, biological evaluation, and in silico studies of new thiadiazolo[3,2-a]pyrimidinone derivatives as potential anticancer agents"],"prefix":"10.1016","volume":"169","author":[{"given":"Nayera I.","family":"Mansour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariam A.","family":"Ghaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia S.","family":"El-Gohary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2025.109366_bb0005","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3390\/nu16060800","article-title":"Healthy lifestyle and cancer risk: modifiable risk factors to prevent cancer","volume":"16","author":"Marino","year":"2024","journal-title":"Nutrients"},{"key":"10.1016\/j.bioorg.2025.109366_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176484","article-title":"Targeting oncogenic kinases: insights on FDA approved tyrosine kinase inhibitors","volume":"970","author":"Hussain","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2025.109366_bb0015","first-page":"201","article-title":"Therapeutic advances of targeting receptor tyrosine kinases in cancer signal transduct target","volume":"9","author":"Tomuleasa","year":"2024","journal-title":"Ther"},{"key":"10.1016\/j.bioorg.2025.109366_bb0020","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s00018-023-04729-4","article-title":"Receptor tyrosine kinase inhibitors in cancer","volume":"80","author":"Ebrahimi","year":"2023","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bioorg.2025.109366_bb0025","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1053\/sonc.2003.50027","article-title":"The epidermal growth factor receptor\u2013tyrosine kinase: a promising therapeutic target in solid tumors","volume":"30","author":"Ritter","year":"2003","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.bioorg.2025.109366_bb0030","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1097\/PAI.0000000000000932","article-title":"Nuclear EGFR expression is associated with poor survival in laryngeal carcinoma","volume":"29","author":"Mariji\u0107","year":"2021","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"10.1016\/j.bioorg.2025.109366_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2407-11-31","article-title":"Epidermal growth factor receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer","volume":"11","author":"Peraldo-Neia","year":"2011","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bioorg.2025.109366_bb0040","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s12253-019-00690-5","article-title":"The association between epidermal growth factor receptor single nucleotide polymorphisms and radiochemotherapy response in cervical cancer","volume":"26","author":"Jin","year":"2020","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.bioorg.2025.109366_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106310","article-title":"Design, synthesis and molecular modeling study of certain EGFR inhibitors with a quinazolinone scaffold as anti-hepatocellular carcinoma and radio-sensitizers","volume":"131","author":"Ghorab","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109366_bb0050","article-title":"Design, synthesis, in vitro and in silico evaluation of anti-colorectal cancer activity of curcumin analogues containing 1,3-diphenyl-1H-pyrazole targeting EGFR tyrosine kinase Biochim","volume":"1867","author":"Doan","year":"2023","journal-title":"Biophys, Acta - Gen. Subj."},{"key":"10.1016\/j.bioorg.2025.109366_bb0055","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1080\/07391102.2023.2204351","article-title":"An assessment of EGFR and HER2 inhibitors with structure activity relationship of fused pyrimidine derivatives for breast cancer: a brief review","volume":"42","author":"Dhiwar","year":"2024","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bioorg.2025.109366_bb0060","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3390\/molecules27030819","article-title":"Structural insight and development of EGFR tyrosine kinase inhibitors","volume":"27","author":"Amelia","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2025.109366_bb0065","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1097\/JTO.0b013e3181f1c7b0","article-title":"Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva lung cancer survival treatment study","volume":"5","author":"Reck","year":"2010","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bioorg.2025.109366_bb0070","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1517\/14656566.6.6.985","article-title":"Gefitinib in non-small cell lung cancer","volume":"6","author":"Tamura","year":"2005","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.bioorg.2025.109366_bb0075","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s40262-016-0440-1","article-title":"Clinical pharmacokinetics and pharmacodynamics of afatinib","volume":"56","author":"Wind","year":"2017","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.bioorg.2025.109366_bb0080","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1042\/BCJ20160583","article-title":"Topoisomerases as anticancer targets","volume":"475","author":"Delgado","year":"2018","journal-title":"Biochem. J."},{"key":"10.1016\/j.bioorg.2025.109366_bb0085","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1021\/acs.jmedchem.9b00726","article-title":"Dual inhibitors of human DNA topoisomerase II and other cancer-related targets","volume":"63","author":"Skok","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109366_bb0090","doi-asserted-by":"crossref","first-page":"6327","DOI":"10.1093\/nar\/gkr258","article-title":"The ancestral role of ATP hydrolysis in type II topoisomerases: prevention of DNA double-strand breaks","volume":"39","author":"Bates","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bioorg.2025.109366_bb0095","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1081\/CNV-120002156","article-title":"DNA topoisomerase II as a target for cancer chemotherapy","volume":"20","author":"Walker","year":"2002","journal-title":"Cancer Invest."},{"key":"10.1016\/j.bioorg.2025.109366_bb0100","first-page":"1504","article-title":"Topoisomerase II inhibitors and poisons, and the influence of cell cycle checkpoints","volume":"24","author":"Darcy","year":"2017","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109366_bb0105","doi-asserted-by":"crossref","first-page":"8947","DOI":"10.1021\/acs.jmedchem.7b01202","article-title":"Discovery of novel topoisomerase II inhibitors by medicinal chemistry approaches","volume":"61","author":"Hu","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109366_bb0110","doi-asserted-by":"crossref","first-page":"659","DOI":"10.3390\/cells12040659","article-title":"Doxorubicin\u2014an agent with multiple mechanisms of anticancer activity","volume":"12","author":"Kciuk","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.bioorg.2025.109366_bb0115","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1212\/WNL.63.12_suppl_6.S15","article-title":"Mechanism of action of mitoxantrone","volume":"63","author":"Fox","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.bioorg.2025.109366_bb0120","first-page":"95","article-title":"Molecular mechanisms of etoposide","volume":"14","author":"Montecucco","year":"2015","journal-title":"EXCLI J."},{"key":"10.1016\/j.bioorg.2025.109366_bb0125","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0163-7258(03)00058-5","article-title":"Catalytic topoisomerase II inhibitors in cancer therapy","volume":"99","author":"Larsen","year":"2003","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bioorg.2025.109366_bb0130","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.3390\/cancers13153675","article-title":"Optimization of new catalytic topoisomerase II inhibitors as an anti-cancer therapy","volume":"13","author":"Matias-Barrios","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.bioorg.2025.109366_bb0135","first-page":"474","article-title":"Possible cardioprotective mechanism of action of dexrazoxane, and probable human topoisomerase II\u03b2 inhibitors: an in silico analysis","volume":"46","author":"Karaku\u015f","year":"2022","journal-title":"J. Fac. Pharm. Ankara"},{"key":"10.1016\/j.bioorg.2025.109366_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jmgm.2018.09.013","article-title":"Pharmacoinformatics analysis of merbarone binding site in human topoisomerase II\u03b1","volume":"86","author":"Tripathi","year":"2019","journal-title":"J. Mol. Graph."},{"key":"10.1016\/j.bioorg.2025.109366_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6769-9-1","article-title":"Catalytic inhibition of topoisomerase II by a novel rationally designed ATP-competitive purine analogue","volume":"9","author":"Ch\u00e8ne","year":"2009","journal-title":"BMC Chem. Biol."},{"key":"10.1016\/j.bioorg.2025.109366_bb0150","doi-asserted-by":"crossref","first-page":"7470","DOI":"10.1158\/0008-5472.CAN-05-0707","article-title":"Substituted purine analogues define a novel structural class of catalytic topoisomerase II inhibitors","volume":"65","author":"Jensen","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.109366_bb0155","doi-asserted-by":"crossref","first-page":"206","DOI":"10.2174\/1385272827666221227120648","article-title":"Nitrogen-containing fused heterocycles: organic synthesis and applications as potential anticancer agents","volume":"27","author":"Ledade","year":"2023","journal-title":"Curr. Org. Chem."},{"key":"10.1016\/j.bioorg.2025.109366_bb0160","doi-asserted-by":"crossref","first-page":"369","DOI":"10.2174\/0115734064278334231211054053","article-title":"Nitrogen-fused heterocycles: empowering anticancer drug discovery","volume":"20","author":"Biswas","year":"2024","journal-title":"Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109366_bb0165","doi-asserted-by":"crossref","first-page":"4411","DOI":"10.1016\/j.ejmech.2011.07.012","article-title":"Synthesis and anticancer evaluation of novel 2-cyclopropylimidazo[2,1-b][1,3,4]-thiadiazole derivatives","volume":"46","author":"Noolvi","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109366_bb0170","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.ejmech.2011.11.013","article-title":"Novel 1,3,4-heterodiazole analogues: synthesis and in-vitro antitumor activity","volume":"47","author":"Taher","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109366_bb0175","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104794","article-title":"Development of adamantane scaffold containing 1,3,4-thiadiazole derivatives: design, synthesis, anti-proliferative activity and molecular docking study targeting EGFR","volume":"110","author":"Wassel","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109366_bb0180","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.3390\/molecules27061814","article-title":"New 1,3,4-thiadiazole derivatives with anticancer activity","volume":"27","author":"Janowska","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2025.109366_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2022.133673","article-title":"Design, synthesis, in silico and biological evaluation of novel 2-amino-1,3,4-thiadiazole based hydrids as B-cell lymphoma-2 inhibitors with potential anticancer effects","volume":"1268","author":"Ibrahim","year":"2022","journal-title":"J. Mol. Str."},{"key":"10.1016\/j.bioorg.2025.109366_bb0190","doi-asserted-by":"crossref","first-page":"17476","DOI":"10.3390\/ijms242417476","article-title":"Synthesis of 1,3,4-thiadiazole derivatives and their anticancer evaluation","volume":"24","author":"Stecoza","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.109366_bb0195","first-page":"580","article-title":"Recent developments of 1,3,4-thiadiazole compounds as anticancer agents","volume":"18","author":"Indelicato","year":"2025","journal-title":"Pharm"},{"key":"10.1016\/j.bioorg.2025.109366_bb0200","doi-asserted-by":"crossref","first-page":"3226","DOI":"10.2174\/1381612822666160224142200","article-title":"Epidermal growth factor receptor (EGFR) and its cross-talks with topoisomerases: challenges and opportunities for multi-target anticancer drugs","volume":"22","author":"Chauhan","year":"2016","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.bioorg.2025.109366_bb0205","doi-asserted-by":"crossref","first-page":"77717","DOI":"10.1039\/C6RA15118C","article-title":"Dual inhibitors of epidermal growth factor receptor and topoisomerase II\u03b1 derived from a quinoline scaffold","volume":"6","author":"Chauhan","year":"2016","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2025.109366_bb0210","doi-asserted-by":"crossref","first-page":"2205043","DOI":"10.1080\/14756366.2023.2205043","article-title":"Novel topoisomerase II\/EGFR dual inhibitors: design, synthesis and docking studies of naphtho[2\u2032,3\u2032:4,5]thiazolo[3,2-a]pyrimidine hybrids as potential anticancer agents with apoptosis inducing activity","volume":"38","author":"Mourad","year":"2023","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109366_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107223","article-title":"Multi-target rational design and synthesis of novel diphenyl-tethered pyrazolopyrimidines targeting EGFR and topoisomerase II with potential DNA intercalation and apoptosis induction","volume":"145","author":"Gaber","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109366_bb0220","doi-asserted-by":"crossref","first-page":"35239","DOI":"10.1039\/D4RA06704E","article-title":"Design, synthesis, and in vitro and in vivo biological evaluation of triazolopyrimidine hybrids as multitarget directed anticancer agents","volume":"14","author":"Adawy","year":"2024","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2025.109366_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105966","article-title":"New phthalimide-based derivatives as EGFR-TK inhibitors: synthesis, biological evaluation, and molecular modeling study","volume":"127","author":"Mansour","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109366_bb0230","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1007\/s00044-014-1114-x","article-title":"New series of benzothiazole and pyrimido[2,1-b]benzothiazole derivatives: synthesis, antitumor activity, EGFR tyrosine kinase inhibitory activity and molecular modeling studies","volume":"24","author":"Gabr","year":"2015","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.bioorg.2025.109366_bb0235","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.3892\/ol.2014.2367","article-title":"Expression of DNA topoisomerase II-\u03b1: clinical significance in laryngeal carcinoma","volume":"8","author":"Feng","year":"2014","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.bioorg.2025.109366_bb0240","doi-asserted-by":"crossref","first-page":"20474","DOI":"10.18632\/oncotarget.4105","article-title":"Catalytic inhibitors of DNA topoisomerase II suppress the androgen receptor signaling and prostate cancer progression","volume":"6","author":"Li","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bioorg.2025.109366_bb0245","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/cncr.22171","article-title":"Validation of a novel immunocytochemical assay for topoisomerase II-\u03b1 and minichromosome maintenance protein 2 expression in cervical cytology","volume":"108","author":"Shroyer","year":"2006","journal-title":"Cancer Cytopathol."},{"key":"10.1016\/j.bioorg.2025.109366_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114376","article-title":"Design, synthesis and biological evaluation of 3-arylisoquinoline derivatives as topoisomerase I and II dual inhibitors for the therapy of liver cancer","volume":"237","author":"Deng","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109366_bb0255","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-019-5631-3","article-title":"Prognostic relevance of topoisomerase II \u03b1 and minichromosome maintenance protein 6 expression in colorectal cancer","volume":"19","author":"Hendricks","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bioorg.2025.109366_bb0260","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-018-4170-7","article-title":"The prognostic significance of topoisomerase II alpha protein in early stage luminal breast cancer","volume":"18","author":"An","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bioorg.2025.109366_bb0265","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.ejmech.2014.07.097","article-title":"Synthesis and in vitro antitumor activity of new series of benzothiazole and pyrimido[2,1-b] benzothiazole derivatives","volume":"85","author":"Gabr","year":"2014","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109366_bb0270","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1007\/BF02252004","article-title":"Reaction of esters of 2-substituted 5-pyrimidinecarboxylic acids with hydrazine hydrate","volume":"35","author":"Tumkevicius","year":"1999","journal-title":"Chem. Heterocycl. Compd."},{"key":"10.1016\/j.bioorg.2025.109366_bb0275","doi-asserted-by":"crossref","first-page":"975","DOI":"10.52711\/0974-360X.2023.00163","article-title":"Synthesis and pharmacological profile of hydrazide compounds","volume":"16","author":"Sadeek","year":"2023","journal-title":"Res. J. Pharm. Technol."},{"key":"10.1016\/j.bioorg.2025.109366_bb0280","doi-asserted-by":"crossref","first-page":"28","DOI":"10.4236\/ijoc.2022.121003","article-title":"Design and synthesis of new compounds derived from phenyl hydrazine and different aldehydes as anticancer agents","volume":"12","author":"Salem","year":"2022","journal-title":"Int. J. Org. Chem."},{"key":"10.1016\/j.bioorg.2025.109366_bb0285","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1080\/17415993.2011.601869","article-title":"Thiosemicarbazides: synthesis and reactions","volume":"32","author":"Metwally","year":"2011","journal-title":"J. Sulphur Chem."},{"key":"10.1016\/j.bioorg.2025.109366_bb0290","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.bioorg.2025.109366_bb0295","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0022-1759(86)90368-6","article-title":"Rapid colorimetric assay for cell growth and survival: modifications to the tetrazolium dye procedure giving improved sensitivity and reliability","volume":"89","author":"Denizot","year":"1986","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.bioorg.2025.109366_bb0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104274","article-title":"Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M)","volume":"105","author":"Shaheen","year":"2020","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109366_bb0305","article-title":"Discovery of novel 9-heterocyclyl substituted 9H-purines as L858R\/T790M\/C797S mutant EGFR tyrosine kinase inhibitors","volume":"186","author":"Lei","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109366_bb0310","first-page":"247","article-title":"Flow cytometric DNA analysis of human cancer cell lines. In cancer cell culture: methods and protocols","volume":"88","author":"Mullen","year":"2004","journal-title":"Methods Mol. Med."},{"key":"10.1016\/j.bioorg.2025.109366_bb0315","first-page":"359","article-title":"Flow cytometric DNA analysis of human cancers and cell lines. In cancer cell culture: methods and protocols","volume":"731","author":"Krueger","year":"2011","journal-title":"Methods Mol. Med."},{"key":"10.1016\/j.bioorg.2025.109366_bb0320","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ejmech.2013.04.006","article-title":"Synthesis, interaction with DNA, cytotoxicity, cell cycle arrest and apoptotic inducing properties of ruthenium(II) molecular \u201clight switch\u201d complexes","volume":"64","author":"Devi","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109366_bb0325","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1756-9966-30-87","article-title":"Apoptosis in cancer: from pathogenesis to treatment","volume":"30","author":"Wong","year":"2011","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.109366_bb0330","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.3390\/ijms23031328","article-title":"The apoptosis paradox in cancer","volume":"23","author":"Morana","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.109366_bb0335","doi-asserted-by":"crossref","first-page":"205","DOI":"10.15171\/apb.2019.024","article-title":"Understanding apoptosis and apoptotic pathways targeted cancer therapeutics","volume":"9","author":"Jan","year":"2019","journal-title":"Adv. Pharm. Bull."},{"key":"10.1016\/j.bioorg.2025.109366_bb0340","doi-asserted-by":"crossref","first-page":"5805","DOI":"10.1007\/s12035-023-03433-5","article-title":"A review on caspases: key regulators of biological activities and apoptosis","volume":"60","author":"Sahoo","year":"2023","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.bioorg.2025.109366_bb0345","doi-asserted-by":"crossref","first-page":"783","DOI":"10.2174\/1389203724666230227115305","article-title":"Caspase-3 activators as anticancer agents","volume":"24","author":"Srivastava","year":"2023","journal-title":"Curr. Protein Pept. Sci."},{"key":"10.1016\/j.bioorg.2025.109366_bb0350","doi-asserted-by":"crossref","first-page":"8585598","DOI":"10.1155\/2022\/8585598","article-title":"Osthole induces apoptosis and caspase-3\/GSDME-dependent pyroptosis via NQO1-mediated ROS generation in HeLa cells","volume":"1","author":"Wang","year":"2022","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.bioorg.2025.109366_bb0355","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00204-014-1448-7","article-title":"The mystery of BCL2 family: BCL-2 proteins and apoptosis: an update","volume":"89","author":"Siddiqui","year":"2015","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.bioorg.2025.109366_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114184","article-title":"Trends in targeting Bcl-2 anti-apoptotic proteins for cancer treatment","volume":"232","author":"Zhang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109366_bb0365","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1517\/17460441.3.6.607","article-title":"The challenge of selecting protein kinase assays for lead discovery optimization","volume":"3","author":"Ma","year":"2008","journal-title":"Expert Opin. Drug Discovery"},{"key":"10.1016\/j.bioorg.2025.109366_bb0370","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.3892\/mmr.2014.3058","article-title":"Establishment and biological characteristics of acquired gefitinib resistance in cell line NCI-H1975\/gefinitib-resistant with epidermal growth factor receptor T790M mutation","volume":"11","author":"Zhao","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.bioorg.2025.109366_bb0375","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.1080\/07391102.2018.1558112","article-title":"Structural insight into the binding mechanism of ATP to EGFR and L858R, and T790M and L858R\/T790M mutants","volume":"37","author":"Salda\u00f1a-Rivera","year":"2019","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.bioorg.2025.109366_bb0380","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1016\/j.bmc.2016.04.032","article-title":"Discovery of 5-(methylthio)pyrimidine derivatives as L858R\/T790M mutant selective epidermal growth factor receptor (EGFR) inhibitors","volume":"24","author":"Xiao","year":"2016","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109366_bb0385","first-page":"99","article-title":"Western blotting (immunoblotting): history, theory, uses, protocol and problems","volume":"75","author":"Sule","year":"2023","journal-title":"Bio Techniques"},{"key":"10.1016\/j.bioorg.2025.109366_bb0390","doi-asserted-by":"crossref","first-page":"46265","DOI":"10.1074\/jbc.M207135200","article-title":"Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor","volume":"277","author":"Stamos","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2025.109366_bb0395","doi-asserted-by":"crossref","first-page":"37041","DOI":"10.1074\/jbc.M506520200","article-title":"Nucleotide-dependent domain movement in the ATPase domain of a human type IIA DNA topoisomerase","volume":"280","author":"Wei","year":"2005","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bioorg.2025.109366_bb0400","author":"MOE"},{"key":"10.1016\/j.bioorg.2025.109366_bb0405","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1021\/acsmedchemlett.9b00381","article-title":"Discovery and optimization of dibenzodiazepinones as allosteric mutant-selective EGFR inhibitors","volume":"10","author":"De Clercq","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.109366_bb0410","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.neuron.2018.08.011","article-title":"Molecular dynamics simulation for all","volume":"99","author":"Hollingsworth","year":"2018","journal-title":"Neuron"},{"key":"10.1016\/j.bioorg.2025.109366_bb0415","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","article-title":"GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers","volume":"1","author":"Abraham","year":"2015","journal-title":"SoftwareX"},{"key":"10.1016\/j.bioorg.2025.109366_bb0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2021.104851","article-title":"In silico methods and tools for drug discovery","volume":"137","author":"Shaker","year":"2021","journal-title":"Comput. Bio. Med."},{"key":"10.1016\/j.bioorg.2025.109366_bb0425","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ddtec.2004.11.007","article-title":"Lead- and drug-like compounds: the rule-of-five revolution","volume":"1","author":"Lipinski","year":"2004","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.bioorg.2025.109366_bb0430","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/jm020017n","article-title":"Molecular properties that influence the oral bioavailability of drug candidates","volume":"45","author":"Veber","year":"2002","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109366_bb0440","unstructured":"https:\/\/www.molinspiration.com\/cgi-bin\/properties."},{"key":"10.1016\/j.bioorg.2025.109366_bb0445","unstructured":"https:\/\/preadmet.bmdrc.kr\/."},{"key":"10.1016\/j.bioorg.2025.109366_bb0450","unstructured":"https:\/\/www.organic-chemistry.org\/prog\/peo\/."},{"key":"10.1016\/j.bioorg.2025.109366_bb0435","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1021\/jm301297f","article-title":"Demystifying brain penetration in central nervous system drug discovery: miniperspective","volume":"56","author":"Di","year":"2013","journal-title":"J. Med. Chem."}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825012465?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206825012465?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T19:21:42Z","timestamp":1768936902000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206825012465"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":90,"alternative-id":["S0045206825012465"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109366","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual topoisomerase II\u03b1\/EGFR-TK inhibitors: Synthesis, biological evaluation, and in silico studies of new thiadiazolo[3,2-a]pyrimidinone derivatives as potential anticancer agents","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109366","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109366"}}